EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with chimeric lysin CHAPSH3b and vancomycin

Ana Catarina Duarte, Lucía Fernández iD, Ana Rodríguez iD, Pilar García

mSphere · 25.03.2025 · 10 (3)

DOI: 10.1128/msphere.01014-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, erschienen am 25.03.2025. Verfasst von Ana Catarina Duarte und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Oviedo, Asturias, Spain. Hauptthemen laut MEDLINE: Staphylococcus epidermidis, Biofilms, Staphylococcus Phages, Vancomycin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MCIN/AEI/10.13039/501100011033/FEDER, UE, EC | H2020 | PRIORITY 'Excellent science' | H2020 Marie Skłodowska-Curie Actions (MSCA), Gobierno del Principado de Asturias (GPA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Staphylococcus epidermidis is the cause of serious skin and prosthetic joint infections despite being a common inhabitant of human body surfaces. However, both the rise in antibiotic resistance in this species and its ability to form biofilms are increasingly limiting the available therapeutic options against these illnesses. In this landscape, phage therapy stands out as an interesting alternative to antibiotics. In the present study, we report the isolation and characterization of a novel virulent phage infecting S. epidermidis ( Staphylococcus phage IPLA-AICAT), which belongs to the Herelleviridae family. The estimated genome size of this virus is 139,941 bp, and sequence analysis demonstrated the absence of antibiotic resistance genes and virulence factors. This phage infects a high proportion (79%) of clinically relevant S. epidermidis strains and exhibits antibiofilm activity. Moreover, a combination of this phage with other antimicrobials, i.e., vancomycin and the lytic protein CHAPSH3b, further improved the reduction in surface-attached bacteria. Notably, the combination of Staphylococcus phage IPLA-AICAT (10 9 PFU/mL) and CHAPSH3b (8 µM), originally designed to target Staphylococcus aureus , was able to reduce the number of viable cells by 3.06 log units in 5-h-old biofilms. In 24-h-old biofilms, the reduction was also significant after 6 h of treatment (2.06 log units) and 24 h of treatment (2.52 log units). These results confirm our previous data regarding the potential of phage-lysin mixtures against staphylococcal biofilms. IMPORTANCE Staphylococcus epidermidis is one of the main causes to device-associated infections mostly due to its ability to form stable biofilms attached to human tissues. Besides the inherent antimicrobial tolerance of biofilms, this microorganism is also increasingly becoming resistant to standard-of-care antibiotics. To fight against this problem, phage therapy is a viable option to complement the available antibiotics in the treatment of recalcitrant infections. This work describes a new phage infecting S. epidermidis clinical strains that is a member of the Herelleviridae family and the combination with other antimicrobials to further improve the reduction of biofilms. Together with the significant progress achieved in the development of diagnostic tools, phages and their derived proteins will bring us much closer to a therapeutic landscape in which we are not so heavily reliant on antibiotics to combat bacterial pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staphylococcus epidermidisBiofilmsStaphylococcus PhagesVancomycinAnti-Bacterial AgentsPhage TherapyHumansGenome, ViralStaphylococcal Infections

Stichwörter der Autor:innen

Staphylococcus epidermidisantibioticbacteriophagebiofilmslytic proteinsynergy

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Oviedo, Asturias, Spain.
  • DairySafe Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.

ORCID-Profile: Lucía Fernández, Ana Rodríguez

Förderung

  • MCIN/AEI/10.13039/501100011033/FEDER, UE
  • EC | H2020 | PRIORITY 'Excellent science' | H2020 Marie Skłodowska-Curie Actions (MSCA)
  • Gobierno del Principado de Asturias (GPA)

Zitieren

APA

Duarte, A. C., Fernández, L., Rodríguez, A., & García, P. (2025). A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with chimeric lysin CHAPSH3b and vancomycin. mSphere, 10(3). https://doi.org/10.1128/msphere.01014-24

Vancouver

Duarte AC, Fernández L, Rodríguez A, García P. A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with chimeric lysin CHAPSH3b and vancomycin. mSphere. 2025;10(3). doi:10.1128/msphere.01014-24

BibTeX
@article{Duarte2025,
  author = {Duarte, Ana Catarina and Fernández, Lucía and Rodríguez, Ana and García, Pilar},
  title = {A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with chimeric lysin CHAPSH3b and vancomycin},
  journal = {mSphere},
  year = {2025},
  volume = {10},
  number = {3},
  doi = {10.1128/msphere.01014-24}
}
Kostenlos starten →